Skip to main content

Hugo Ramos Abellan

Institutions of which they are part

Research technician
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Hugo Ramos Abellan

Institutions of which they are part

Research technician
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Diabetis i metabolisme

IP: Rafael Simó Canonge
Collaborators: Josep A Villena Delgado, Carles Zafon Llopis, Cristina Hernández Pascual, David Martinez Selva, Rosario Pardo Diaz, Angel Michael Ortiz Zúñiga, Andreea Ciudin Mihai, Fiorella Ximena Palmas Candia, Ana Maria Ortiz de Urbina Olive, Monica Sanchez Bartres, Lorena Ramos Pérez, Marc Rivas Agudo, Diabetis i metabolisme, Anna Casteras Román, Alejandra Planas Vilaseca, Betina Biagetti Biagetti, Judit Amigó Farran, Mercè Abad Martín, Marta Comas Martínez, Hugo Ramos Abellan, Rosa Burgos Peláez, David Sabater Martínez, Olga Simó Servat, Patricia Bogdanov Baruj, Maria Llorian Salvador, Enzamaría Fidilio Meli
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00655
Duration: 01/01/2022 - 30/06/2025

Proyecto PDC2022-133991-I00 financiado por MICIU/AEI/10.13039/501100011033 y por la Unión Europea Next GenerationEU/ PRTR

IP: Rafael Simó Canonge
Collaborators: Anna Duarri Piqué, Cristina Hernández Pascual, Hugo Ramos Abellan, Patricia Bogdanov Baruj
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 128570
Reference: PDC2022-133991-I00
Duration: 01/12/2022 - 30/11/2024

Ministerio de Ciencia

Bloqueo intraocular de la hemopexina: una nueva estrategia para tratar el edema macular diabético

IP: Rafael Simó Canonge
Collaborators: Hugo Ramos Abellan, Patricia Bogdanov Baruj
Funding agency: Instituto de Salud Carlos III
Funding: 78100
Reference: DTS19/00171
Duration: 01/01/2020 - 31/12/2021

Nuevas perspectivas en mediadores inflamatorios en la patogenia del edema macular diabético: implicaciones terapéuticas

IP: Cristina Hernández Pascual
Collaborators: Hugo Ramos Abellan, Patricia Bogdanov Baruj
Funding agency: Instituto de Salud Carlos III
Funding: 149132.5
Reference: PI19/01215
Duration: 01/01/2020 - 31/12/2022

Related news

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

Related professionals

Manuel Escobar Amores

Manuel Escobar Amores

Main researcher
Molecular Imaging and Therapy
Read more
Margarida Capell Maymo

Margarida Capell Maymo

Administration and Management
Clinical Neuroimmunology
Read more
Carlos  González Cruz

Carlos González Cruz

Predoctoral researcher
Biomedical Research in Melanoma
Read more
Cristina Losada Gimenez

Cristina Losada Gimenez

Research technician
Stroke research
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.